# OnCo record ipilimumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ipilimumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ipilimumab" ;
  schema:name "Ipilimumab"@en ;
  schema:description "Ipilimumab was the first checkpoint inhibitor (2011), and proved the immune system could be unleashed against cancer."@en ;
  schema:url <https://onco.cc/drugs/ipilimumab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ipilimumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q2459042> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ipilimumab>, <https://www.nice.org.uk/guidance/ta1065>, <https://www.nice.org.uk/guidance/ta724> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-CTLA-4)" ;
  schema:alternateName "Yervoy" ;
  onco:approval "US 2011: Metastatic melanoma", "England (NICE) 2025: Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with nivolumab", "England (NICE) 2021: Untreated metastatic non-small-cell lung cancer, with nivolumab and two cycles of platinum doublet chemotherapy: not recommended" ;
  onco:acceleratedApproval "US 2018-07-10: In combination with nivolumab, is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan", "US 2020-03-10: In combination with nivolumab, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib" ;
  onco:acceleratedApprovalConfirmed "US 2025-04-08: In combination with nivolumab, is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan", "US 2025-04-11: In combination with nivolumab, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/mesothelioma/>, <https://onco.cc/cancers/msi-high-colorectal/>, <https://onco.cc/cancers/advanced-melanoma/>, <https://onco.cc/cancers/stage-iii-melanoma/>, <https://onco.cc/cancers/mucosal-melanoma/>, <https://onco.cc/cancers/acral-melanoma/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/ctla4/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/checkmate-067/>, <https://onco.cc/trials/nct03873402/>, <https://onco.cc/trials/nct06581406/>, <https://onco.cc/trials/nct06097728/>, <https://onco.cc/trials/nct05987332/>, <https://onco.cc/trials/nct06946797/>, <https://onco.cc/trials/nct07227012/>, <https://onco.cc/trials/nct06784648/>, <https://onco.cc/trials/nct07291076/>, <https://onco.cc/trials/nct07227415/>, <https://onco.cc/trials/nct06362369/>, <https://onco.cc/trials/nct07293351/>, <https://onco.cc/trials/nct03907852/>, <https://onco.cc/trials/nct03647163/>, <https://onco.cc/trials/nct07563738/>, <https://onco.cc/trials/nct06047379/>, <https://onco.cc/trials/nct03899155/>, <https://onco.cc/trials/nct03036098/>, <https://onco.cc/trials/nct05584670/>, <https://onco.cc/trials/nct05144854/>, <https://onco.cc/trials/nct03865082/>, <https://onco.cc/trials/nct05533697/>, <https://onco.cc/trials/checkmate-227/>, <https://onco.cc/trials/checkmate-9la/> ;
  onco:people <https://onco.cc/people/inge-marie-svane/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-niche-2-nejm-2024/> .